|
Q1 2020
|
||
$m
|
% change
|
||
Actual
|
CER1
|
||
Total Revenue
|
6,354
|
16
|
17
|
Product Sales
|
6,311
|
15
|
17
|
Collaboration Revenue
|
43
|
69
|
70
|
|
|
|
|
Reported2 EPS3
|
$0.59
|
27
|
33
|
Core4 EPS
|
$1.05
|
17
|
21
|
|
Q1 2020
|
||
$m
|
% change
|
||
Actual
|
CER
|
||
Tagrisso: Product
Sales
|
982
|
56
|
58
|
Imfinzi: Product
Sales
|
462
|
57
|
57
|
Lynparza: Product
Sales
|
397
|
67
|
69
|
Calquence: Product
Sales
|
88
|
n/m12
|
n/m
|
Enhertu: Collaboration
Revenue
|
14
|
n/m
|
n/m
|
|
Q1 2020
|
||
$m
|
% change
|
||
Actual
|
CER
|
||
Farxiga: Total
Revenue
|
407
|
16
|
19
|
Brilinta: Product
Sales
|
408
|
17
|
19
|
Bydureon: Product
Sales
|
100
|
(30)
|
(29)
|
Lokelma: Product
Sales
|
11
|
n/m
|
n/m
|
Roxadustat: Collaboration Revenue
|
3
|
n/m
|
n/m
|
|
Q1 2020
|
||
$m
|
% change
|
||
Actual
|
CER
|
||
Symbicort: Product
Sales
|
790
|
35
|
36
|
Pulmicort: Product
Sales
|
380
|
(1)
|
-
|
Fasenra: Product
Sales
|
199
|
54
|
55
|
Regulatory
approvals
|
- Imfinzi -
ES[11]-SCLC[12] (US)
- Enhertu -
breast cancer (3rd line[13],
HER2+[14])
(JP)
- Koselugo (selumetinib)
- NF1[15] (US)
- Lokelma -
hyperkalaemia (JP)
|
Regulatory
submission acceptances and/or submissions
|
- Lynparza -
prostate cancer (2nd line): regulatory submission (JP)
- Koselugo -
NF1: regulatory submission acceptance (EU)
|
Major
Phase III data readouts or other significant
developments
|
- Tagrisso -
adjuvant NSCLC[16] (EGFRm):
unblinded for overwhelming efficacy
- Imfinzi -
ES-SCLC: OS[17] confirmed
- Imfinzi +
treme - ES-SCLC: primary endpoint not met
- Imfinzi +/-
treme - bladder cancer (1st line[18]): primary
endpoints not met
- Lynparza -
prostate cancer: secondary OS endpoint met
- Lynparza -
pancreatic cancer: orphan designation (JP)
-
cediranib - ovarian cancer (2nd line[19]): primary
endpoint not met
- Farxiga -
CKD[20]:
primary endpoint met early
|
Timing
|
News
flow
|
Q2 2020
|
- Imfinzi -
ES-SCLC: regulatory submission (CN)
- Lynparza -
ovarian cancer (1st line) (PAOLA-1): regulatory decision
(US)
- Lynparza -
breast cancer (BRCAm[21]): regulatory
decision (CN)
- Lynparza -
prostate cancer (2nd line): regulatory decision (US)
- Enhertu -
gastric cancer (3rd line, HER2+): regulatory
submission
- Forxiga -
T2D[22] CVOT[23]:
regulatory decision (CN)
- Farxiga -
HF[24] CVOT:
regulatory decision (US)
- Symbicort -
mild asthma: regulatory submission (EU)
- Bevespi -
COPD[25]:
regulatory decision (CN)
|
H2 2020
|
- Tagrisso -
adjuvant NSCLC (EGFRm): regulatory submission
- Imfinzi -
unresectable[26], Stage III NSCLC
(PACIFIC-2): data readout
- Imfinzi -
ES-SCLC: regulatory decision (EU, JP)
- Imfinzi +/-
treme - liver cancer (1st line): data readout
- Lynparza -
ovarian cancer (1st line) (PAOLA-1): regulatory decision
(EU)
- Lynparza -
ovarian cancer (3rd line, BRCAm): regulatory submission
(US)
- Lynparza -
pancreatic cancer (1st line, BRCAm): regulatory decision
(EU)
- Lynparza -
prostate cancer (2nd line): regulatory decision (EU)
- Enhertu -
breast cancer (3rd line, HER2+): regulatory submission
(EU)
- Calquence -
CLL[27]:
regulatory decision (EU)
- Forxiga -
HF CVOT: regulatory decision (EU, JP, CN)
- Farxiga -
CKD: regulatory submission
- Brilinta/Brilique -
CAD[28]/T2D CVOT:
regulatory decision (US, EU)
-
roxadustat - anaemia in CKD: regulatory decision (US)
- Symbicort -
mild asthma: regulatory decision (CN)
- Fasenra -
nasal polyposis[29]: data
readout
-
PT010 - COPD: regulatory decision (US, EU)
-
PT027 - asthma: data readout
-
tezepelumab - severe asthma: data readout
-
anifrolumab - lupus (SLE[30]): regulatory
submission
|
2021
|
- Imfinzi -
unresectable, Stage III NSCLC (PACIFIC-2): regulatory
submission
- Imfinzi -
adjuvant NSCLC: data readout, regulatory submission
- Imfinzi -
liver cancer (locoregional): data readout, regulatory
submission
- Imfinzi +/-
treme - NSCLC (1st line) (POSEIDON): data readout (OS), regulatory
submission
- Imfinzi +/-
treme - liver cancer (1st line): regulatory submission
- Imfinzi +/-
treme - head & neck cancer (1st line): data readout, regulatory
submission
- Lynparza -
adjuvant breast cancer: data readout, regulatory
submission
- Lynparza -
prostate cancer (2nd line): regulatory decision (JP)
- Lynparza -
prostate cancer (1st line, castration-resistant): data readout,
regulatory submission
- Enhertu -
breast cancer (2nd line, HER2+): data readout, regulatory
submission
- Enhertu -
breast cancer (3rd line, HER2+) (Phase III): data
readout
- Enhertu -
breast cancer (HER2-low[31]): data
readout
- Calquence -
CLL: regulatory decision (JP)
- Koselugo -
NF1: regulatory decision (EU)
-
roxadustat - anaemia in myelodysplastic syndrome[32]: data
readout
- Fasenra -
nasal polyposis: regulatory submission
-
PT027 - asthma: regulatory submission
-
tezepelumab - severe asthma: regulatory submission
|
|
Q1 2020
|
|||
$m
|
|
% change
|
||
% of total
|
Actual
|
CER
|
||
Oncology
|
2,518
|
40
|
33
|
34
|
BioPharmaceuticals
|
2,657
|
42
|
15
|
16
|
New CVRM
|
1,102
|
17
|
7
|
8
|
Respiratory & Immunology
|
1,555
|
24
|
21
|
22
|
Other
medicines
|
1,179
|
19
|
(8)
|
(6)
|
|
|
|
|
|
Total
|
6,354
|
100
|
16
|
17
|
Medicine
|
Therapy Area
|
Q1 2020
|
|||
$m
|
% of total
|
% change
|
|||
Actual
|
CER
|
||||
Tagrisso
|
Oncology
|
982
|
15
|
56
|
58
|
Symbicort
|
Respiratory
|
790
|
12
|
35
|
36
|
Imfinzi
|
Oncology
|
462
|
7
|
57
|
57
|
Brilinta
|
CVRM
|
408
|
6
|
17
|
19
|
Farxiga
|
CVRM
|
407
|
6
|
16
|
19
|
Lynparza
|
Oncology
|
397
|
6
|
67
|
69
|
Pulmicort
|
Respiratory
|
380
|
6
|
(1)
|
-
|
Nexium
|
Other medicines
|
348
|
5
|
(6)
|
(5)
|
Crestor
|
CVRM
|
302
|
5
|
(10)
|
(8)
|
Zoladex
|
Oncology
|
228
|
4
|
16
|
19
|
|
|
|
|
|
|
Total
|
|
4,704
|
74
|
26
|
28
|
|
Q1 2020
|
|||
$m
|
% of total
|
% change
|
||
Actual
|
CER
|
|||
Enhertu: profit
share
|
14
|
33
|
n/m
|
n/m
|
Roxadustat: profit share
|
3
|
7
|
n/m
|
n/m
|
Other Ongoing Collaboration Revenue
|
26
|
60
|
4
|
5
|
|
|
|
|
|
Total
|
43
|
100
|
69
|
70
|
Therapy area
|
Medicine
|
Q1 2020
|
|||
$m
|
% of total
|
% change
|
|||
Actual
|
CER
|
||||
Product Sales: Oncology
|
Tagrisso
|
982
|
16
|
56
|
58
|
Imfinzi
|
462
|
7
|
57
|
57
|
|
Lynparza
|
397
|
6
|
67
|
69
|
|
Calquence
|
88
|
1
|
n/m
|
n/m
|
|
Zoladex
|
225
|
4
|
16
|
19
|
|
Faslodex
|
166
|
3
|
(35)
|
(34)
|
|
Iressa
|
77
|
1
|
(42)
|
(41)
|
|
Arimidex
|
50
|
1
|
(1)
|
1
|
|
Casodex
|
42
|
1
|
(12)
|
(10)
|
|
Others
|
13
|
-
|
(37)
|
(36)
|
|
Total Oncology
|
2,502
|
40
|
32
|
34
|
|
Product Sales: BioPharmaceuticals - CVRM
|
Farxiga
|
405
|
6
|
16
|
19
|
Brilinta
|
408
|
6
|
17
|
19
|
|
Bydureon
|
100
|
2
|
(30)
|
(29)
|
|
Onglyza
|
141
|
2
|
(8)
|
(6)
|
|
Byetta
|
20
|
-
|
(32)
|
(31)
|
|
Other diabetes
|
13
|
-
|
16
|
18
|
|
Lokelma
|
11
|
-
|
n/m
|
n/m
|
|
Crestor
|
301
|
5
|
(10)
|
(9)
|
|
Seloken/Toprol-XL
|
177
|
3
|
(21)
|
(18)
|
|
Atacand
|
66
|
1
|
33
|
36
|
|
Others
|
59
|
1
|
(18)
|
(17)
|
|
BioPharmaceuticals: total CVRM
|
1,701
|
27
|
(1)
|
1
|
|
Product Sales: BioPharmaceuticals - Respiratory &
Immunology
|
Symbicort
|
790
|
13
|
35
|
36
|
Pulmicort
|
380
|
6
|
(1)
|
-
|
|
Fasenra
|
199
|
3
|
54
|
55
|
|
Daliresp/Daxas
|
53
|
1
|
11
|
12
|
|
Bevespi
|
12
|
-
|
22
|
22
|
|
Breztri
|
4
|
-
|
n/m
|
n/m
|
|
Others
|
113
|
2
|
(11)
|
(10)
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,551
|
25
|
21
|
22
|
|
Product Sales: other medicines
|
Nexium
|
338
|
5
|
(7)
|
(6)
|
Synagis
|
85
|
1
|
61
|
61
|
|
Losec/Prilosec
|
54
|
1
|
(30)
|
(28)
|
|
Seroquel XR/IR
|
36
|
1
|
(4)
|
(3)
|
|
Others
|
44
|
1
|
(8)
|
(7)
|
|
Total other medicines
|
557
|
9
|
(4)
|
(3)
|
|
|
Total Product Sales
|
6,311
|
100
|
15
|
17
|
|
|
|
|
|
|
Total Collaboration Revenue
|
43
|
|
69
|
70
|
|
|
|
|
|
|
|
Total Revenue
|
6,354
|
|
16
|
17
|
|
Q1 2020
|
|||
$m
|
% of total
|
% change
|
||
Actual
|
CER
|
|||
Emerging Markets
|
2,273
|
36
|
13
|
16
|
China
|
1,416
|
22
|
14
|
17
|
Ex-China
|
857
|
14
|
12
|
15
|
|
|
|
|
|
US
|
2,091
|
33
|
16
|
16
|
|
|
|
|
|
Europe
|
1,204
|
19
|
22
|
25
|
|
|
|
|
|
Established RoW
|
786
|
12
|
13
|
13
|
Japan
|
553
|
9
|
10
|
8
|
Canada
|
156
|
2
|
37
|
36
|
Other Established RoW
|
77
|
1
|
(1)
|
5
|
|
|
|
|
|
Total
|
6,354
|
100
|
16
|
17
|
|
Q1 2020
|
|||
$m
|
% of total
|
% change
|
||
Actual
|
CER
|
|||
Oncology
|
711
|
31
|
45
|
49
|
BioPharmaceuticals
|
872
|
38
|
15
|
18
|
New CVRM
|
332
|
15
|
39
|
43
|
Respiratory & Immunology
|
540
|
24
|
4
|
6
|
Other medicines
|
690
|
30
|
(9)
|
(7)
|
|
|
|
|
|
Total
|
2,273
|
100
|
13
|
16
|
|
Q1 2020
|
||
$m
|
% change
|
||
Actual
|
CER
|
||
Tagrisso
|
280
|
n/m
|
n/m
|
Forxiga
|
142
|
49
|
55
|
Brilinta
|
134
|
38
|
42
|
Lynparza
|
55
|
n/m
|
n/m
|
Imfinzi
|
33
|
n/m
|
n/m
|
|
Q1 2020
|
||
$m
|
% change
|
||
Actual
|
CER
|
||
Russia
|
84
|
72
|
66
|
Brazil
|
89
|
(5)
|
6
|
Ex-Brazil Latin America
|
108
|
7
|
18
|
Ex-China Asia Pacific
|
311
|
11
|
12
|
Middle East and Africa
|
265
|
11
|
12
|
|
Q1 2020
|
Q1 2019
|
% change
|
||
$m
|
$m
|
Actual
|
CER
|
||
Total Revenue
|
6,354
|
5,491
|
16
|
17
|
|
Product Sales
|
6,311
|
5,465
|
15
|
17
|
|
Collaboration Revenue
|
43
|
26
|
69
|
70
|
|
|
|
|
|
|
|
Cost of Sales
|
(1,420)
|
(1,129)
|
26
|
26
|
|
|
|
|
|
|
|
Gross Profit
|
4,934
|
4,362
|
13
|
15
|
|
Gross Margin
|
77.5%
|
79.3%
|
(2)
|
(2)
|
|
|
|
|
|
|
|
Distribution Expense
|
(87)
|
(78)
|
11
|
13
|
|
% Total Revenue
|
1.4%
|
1.4%
|
-
|
-
|
|
R&D Expense
|
(1,388)
|
(1,266)
|
10
|
10
|
|
% Total Revenue
|
21.8%
|
23.1%
|
1
|
2
|
|
SG&A Expense
|
(2,719)
|
(2,514)
|
8
|
9
|
|
% Total Revenue
|
42.8%
|
45.8%
|
3
|
3
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
480
|
593
|
(19)
|
(19)
|
|
% Total Revenue
|
7.6%
|
10.8%
|
(3)
|
(3)
|
|
|
|
|
|
|
|
Operating Profit
|
1,220
|
1,097
|
11
|
16
|
|
Operating Profit Margin
|
19.2%
|
20.0%
|
(1)
|
-
|
|
|
|
|
|
|
|
Net Finance Expense
|
(281)
|
(312)
|
(10)
|
(9)
|
|
Joint Ventures and Associates
|
(4)
|
(27)
|
(85)
|
(85)
|
|
|
|
|
|
|
|
Profit Before Tax
|
935
|
758
|
23
|
29
|
|
|
|
|
|
|
|
Taxation
|
(185)
|
(195)
|
(5)
|
(1)
|
|
Tax Rate
|
20%
|
26%
|
|
|
|
|
|
|
|
||
Profit After Tax
|
750
|
563
|
33
|
40
|
|
|
|
|
|
|
|
EPS
|
0.59
|
0.47
|
27
|
33
|
|
Q1 2020
|
Q1 2019
|
% change
|
|
$m
|
$m
|
Actual
|
CER
|
|
Reported Profit Before Tax
|
935
|
758
|
23
|
29
|
Net Finance Expense
|
281
|
312
|
(10)
|
(9)
|
Joint Ventures and Associates
|
4
|
27
|
(85)
|
(85)
|
Depreciation, Amortisation and Impairment
|
841
|
676
|
24
|
26
|
|
|
|
|
|
EBITDA
|
2,061
|
1,773
|
16
|
20
|
Q1 2020
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Diabetes Alliance
|
Other
|
Core
|
Core % change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross Profit
|
4,934
|
19
|
17
|
-
|
5
|
4,975
|
12
|
14
|
Gross Profit Margin
|
77.5%
|
|
|
|
|
78.1%
|
-2
|
-2
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(87)
|
-
|
-
|
-
|
-
|
(87)
|
11
|
13
|
R&D Expense
|
(1,388)
|
11
|
42
|
-
|
(1)
|
(1,336)
|
9
|
9
|
SG&A Expense
|
(2,719)
|
25
|
449
|
67
|
1
|
(2,177)
|
5
|
7
|
Total Operating Expense
|
(4,194)
|
36
|
491
|
67
|
-
|
(3,600)
|
7
|
8
|
|
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
480
|
(2)
|
1
|
-
|
-
|
479
|
(19)
|
(19)
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
1,220
|
53
|
509
|
67
|
5
|
1,854
|
12
|
16
|
Operating Profit Margin
|
19.2%
|
|
|
|
|
29.2%
|
-1
|
-
|
|
|
|
|
|
|
|
|
|
Net Finance Expense
|
(281)
|
-
|
-
|
57
|
55
|
(169)
|
(11)
|
(11)
|
Taxation
|
(185)
|
(11)
|
(107)
|
(31)
|
-
|
(334)
|
1
|
5
|
|
|
|
|
|
|
|
|
|
EPS
|
$0.59
|
$0.03
|
$0.31
|
$0.07
|
$0.05
|
$1.05
|
17
|
21
|
|
Q1 2020
|
Q1 2019
|
Change
|
$m
|
$m
|
$m
|
|
Reported Operating Profit
|
1,220
|
1,097
|
123
|
Depreciation, Amortisation and Impairment
|
841
|
676
|
165
|
|
|
|
|
Increase in Working Capital and Short-Term Provisions
|
(445)
|
(710)
|
265
|
Gains on Disposal of Intangible Assets
|
(358)
|
(512)
|
154
|
Non-Cash and Other Movements
|
(462)
|
(396)
|
(66)
|
Interest Paid
|
(180)
|
(208)
|
28
|
Taxation Paid
|
(477)
|
(334)
|
(143)
|
|
|
|
|
Net Cash Inflow/(Outflow) from Operating Activities
|
139
|
(387)
|
526
|
Net Cash Inflow/(Outflow) before Financing Activities
|
148
|
(59)
|
207
|
Net Cash Outflow from Financing Activities
|
(2,362)
|
(698)
|
(1,664)
|
|
At 31
Mar 2020
|
At 31
Dec 2019
|
At 31
Mar 2019
|
$m
|
$m
|
$m
|
|
Cash and Cash Equivalents
|
3,413
|
5,369
|
4,136
|
Other Investments
|
804
|
911
|
876
|
|
|
|
|
Cash and Investments
|
4,217
|
6,280
|
5,012
|
|
|
|
|
Overdrafts and Short-Term Borrowings
|
(691)
|
(225)
|
(2,044)
|
Lease Liabilities
|
(653)
|
(675)
|
(714)
|
Current Instalments of Loans
|
(1,598)
|
(1,597)
|
(1,500)
|
Loans Due After One Year
|
(15,634)
|
(15,730)
|
(17,320)
|
|
|
|
|
Interest-Bearing Loans and Borrowings (Gross Debt)
|
(18,576)
|
(18,227)
|
(21,578)
|
|
|
|
|
Net Derivatives
|
(54)
|
43
|
295
|
Net Debt
|
(14,413)
|
(11,904)
|
(16,271)
|
|
Average Exchange
Rates versus USD
|
|
Annual Impact of 5% Strengthening in Exchange Rate versus USD
($m)[35]
|
|||
Currency
|
Primary Relevance
|
FY 2019[36]
|
Q1 2020[37]
|
% change
|
Product Sales
|
Core Operating Profit
|
CNY
|
Product
Sales
|
6.92
|
6.99
|
(1)
|
288
|
190
|
EUR
|
Product
Sales
|
0.89
|
0.91
|
(1)
|
171
|
68
|
JPY
|
Product
Sales
|
108.98
|
108.91
|
-
|
139
|
98
|
Other[38]
|
|
|
|
|
231
|
123
|
|
|
|
|
|
|
|
GBP
|
Operating
Expense
|
0.78
|
0.78
|
-
|
27
|
(93)
|
SEK
|
Operating
Expense
|
9.46
|
9.67
|
(2)
|
5
|
(51)
|
New
molecular entities and major lifecycle events for medicines in
Phase III trials or under regulatory review
|
17
|
Oncology
- Tagrisso -
NSCLC
- Imfinzi -
multiple cancers
- Lynparza -
multiple cancers
- Enhertu -
breast and other cancers
-
capivasertib - breast cancer
- Calquence -
blood cancers
-
tremelimumab - multiple cancers
-
savolitinib - NSCLC[40]
CVRM
- Farxiga -
multiple indications
-
roxadustat - anaemia in CKD
Respiratory & Immunology
- Fasenra -
multiple indications
- Breztri -
asthma
-
PT027 - asthma
-
tezepelumab - severe asthma
-
nirsevimab - respiratory syncytial virus
-
anifrolumab - lupus (SLE)
-
brazikumab[41] -
inflammatory bowel disease
|
Total
projects
in
clinical pipeline
|
167
|
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
ADAURA
|
Adjuvant
EGFRm NSCLC
|
Placebo
or Tagrisso
|
FPCD[42]
Q4
2015
LPCD[43]
Q1
2019
|
Trial
unblinded early due to overwhelming efficacy
|
Phase
III
LAURA
|
Locally
advanced, unresectable EGFRm NSCLC
|
Placebo
or Tagrisso
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
FLAURA2
|
1st-line
EGFRm NSCLC
|
Tagrisso or Tagrisso + platinum-based
chemotherapy doublet
|
FPCD
Q4
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
AEGEAN
|
Neo-adjuvant
(before surgery) NSCLC
|
SoC
chemotherapy +/- Imfinzi,
followed
by
surgery,
followed by placebo or Imfinzi
|
FPCD
Q1
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
ADJUVANT
BR.31[45]
|
Stage
Ib-IIIa NSCLC
|
Placebo
or
Imfinzi
|
FPCD
Q1
2015
LPCD
Q1
2020
First
data anticipated
2021
|
Recruitment
completed
|
Phase
III
PACIFIC-2
|
Stage
III unresected locally advanced NSCLC
(concurrent
CRT)
|
Placebo
or
Imfinzi
|
FPCD
Q2
2018
LPCD
Q3
2019
First
data anticipated
H2
2020
|
Recruitment
completed
|
Phase
III
ADRIATIC
|
Limited-
stage
SCLC
|
Concurrent
CRT,
followed
by
placebo
or
Imfinzi or Imfinzi + treme
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
POSEIDON
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q2
2017
LPCD
Q4
2018
OS data
anticipated
2021
|
PFS[46] primary
endpoint met
|
Phase
III
CASPIAN
|
ES-SCLC
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q1
2017
LPCD
Q2
2018
|
OS
primary endpoint met for Imfinzi monotherapy
arm
OS
primary endpoint not met for Imfinzi + treme
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
POTOMAC
|
Non-muscle
invasive bladder cancer
|
SoC
BCG[47] or SoC BCG
+ Imfinzi
|
FPCD
Q4
2018
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
NIAGARA
|
Muscle-invasive
bladder cancer
|
Neo-adjuvant
cisplatin and gemcitabine SoC chemotherapy or SoC
+ Imfinzi, followed by
adjuvant placebo or Imfinzi
|
FPCD
Q4
2018
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
EMERALD-1
|
Locoregional
HCC[48]
|
TACE[49] followed
by placebo or TACE + Imfinzi, followed by Imfinzi +
bevacizumab
or
TACE
+ Imfinzi
followed
by Imfinzi
|
FPCD
Q1
2019
First
data
anticipated
2021
|
Recruitment
ongoing
|
Phase
III
EMERALD-2
|
Locoregional
HCC at high risk of recurrence after surgery or radiofrequency
ablation
|
Adjuvant Imfinzi or Imfinzi +
bevacizumab
|
FPCD
Q2
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
CALLA
|
Locally
advanced cervical cancer
|
CRT or
CRT + Imfinzi,
followed by placebo or Imfinzi
|
FPCD
Q1
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
DANUBE
|
Stage
IV, 1st-line cisplatin chemotherapy- eligible/ineligible bladder
cancer
|
SoC
chemotherapy or Imfinzi or Imfinzi + treme
|
FPCD
Q4
2015
LPCD
Q1
2017
|
Primary
endpoints not met
|
Phase
III
NILE
|
Stage
IV, 1st-line cisplatin chemotherapy- eligible bladder
cancer
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
Ongoing
|
Phase
III
KESTREL
|
Stage
IV, 1st-line HNSCC[50]
|
SoC
or Imfinzi or Imfinzi + treme
|
FPCD
Q4
2015
LPCD
Q1
2017
First
data
anticipated
2021
|
Recruitment
completed
|
Phase
III
HIMALAYA
|
Stage
IV, 1st-line unresectable HCC
|
Sorafenib
or Imfinzi or Imfinzi + treme
|
FPCD
Q4
2017
LPCD
Q4
2019
First
data
anticipated
H2
2020
|
Recruitment
completed
Orphan
Drug Designation (US)[51]
|
Phase
III
TOPAZ-1
|
Stage
IV, 1st-line biliary-tract cancer
|
Gemcitabine
and cisplatin SoC chemotherapy or SoC + Imfinzi
|
FPCD
Q2
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
OlympiA
|
Adjuvant
BRCAm breast cancer
|
SoC
placebo or Lynparza
|
FPCD
Q2
2014
LPCD
Q2
2019
First
data anticipated
2021
|
Recruitment
completed
|
Phase
III
PROfound
|
Metastatic
castration-resistant 2nd-line+ HRRm
prostate
cancer
|
SoC
(abiraterone or enzalutamide) or Lynparza
|
FPCD
Q2
2017
LPCD
Q4
2018
|
Primary
endpoint met
Priority
Review (US)
|
Phase
III
PAOLA-1[52]
|
Advanced
1st-line
ovarian
cancer
|
Bevacizumab
maintenance or
bevacizumab
+
Lynparza maintenance
|
FPCD
Q2
2015
LPCD
Q2
2018
|
Primary
endpoint met
Priority
Review (US)
|
Phase
III
GY004[53]
|
Recurrent
platinum-sensitive ovarian cancer
|
SoC
chemotherapy or Lynparza or cediranib
+ Lynparza
|
FPCD
Q1
2016
LPCD
Q4
2017
|
Primary
endpoint not met
|
Phase
II/III
GY00553
|
Recurrent
platinum-resistant/refractory ovarian cancer
|
SoC
chemotherapy or cediranib or cediranib + Lynparza
|
FPCD
Q2
2016
(Phase
II)
FPCD
Q1
2019
(Phase
III)
First
data
anticipated
2021+
|
Recruitment
ongoing
(Phase
III component)
|
Phase
III
DuO-O
|
Advanced
1st-line
ovarian
cancer
|
Chemotherapy
+
bevacizumab
or
chemotherapy
+
bevacizumab
+
Imfinzi +/-
Lynparza maintenance
|
FPCD
Q1 2019
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
PROpel
|
Stage
IV, advanced, castration-resistant prostate cancer
|
Abiraterone
or
abiraterone
+
Lynparza
|
FPCD
Q4
2018
First
data
anticipated
2021
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
II
DESTINY-Breast01
|
Stage
IV, HER2+ (IHC[54] 3+ and IHC
2+/ISH[55]+) breast cancer
post trastuzumab emtansine
|
Enhertu
(single
arm)
|
FPCD
Q4
2017
LPCD
Q4
2018
|
Primary
objective met
Breakthrough
Therapy Designation (US)
Approval
(JP), accelerated approval (US)
|
Phase
III
DESTINY-Breast02
|
Stage
IV, HER2+ (IHC 3+ and IHC 2+/ISH+) breast cancer post trastuzumab
emtansine
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2018
First
data anticipated
2021
|
Recruitment ongoing
|
Phase
III
DESTINY-Breast03
|
Stage
IV, HER2+ (IHC 3+ and IHC 2+/ISH+) breast cancer
|
Trastuzumab
emtansine or Enhertu
|
FPCD
Q4
2018
First
data anticipated
2021
|
Recruitment ongoing
|
Phase
III
DESTINY-Breast04
|
Stage
IV, HER2-low (IHC 1+/2+) breast cancer
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2018
First
data anticipated
2021
|
Recruitment ongoing
|
Phase
II
DESTINY-Gastric01
|
Stage
IV, HER2+ (IHC 3+ and IHC 2+/ISH+) gastric cancer
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2017
LPCD
Q2
2019
|
Primary
endpoint met
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
Farxiga
|
|
||||
Phase
III
DAPA-HF
|
c.4,500
patients with HF and reduced ejection fraction, with and without
T2D
|
Arm
1: Farxiga 10mg
or 5 mg QD[56] +
SoC
Arm 2:
placebo + SoC
|
Time to
first occurrence of CV death or hospitalisation due to HF or an
urgent HF visit
|
FPCD
Q1
2017
LPCD
Q4
2018
|
Primary
endpoint met
Fast
Track designation (US)
|
Phase
III
DELIVER
|
c.4,700
patients with HF and preserved ejection fraction, with and without
T2D
|
Arm
1: Farxiga 10mg
QD
Arm 2:
placebo
|
Time to
first occurrence of CV death or worsening HF
|
FPCD
Q4
2018
First
data anticipated 2021+
|
Recruitment
ongoing
Fast
Track designation (US)
|
Phase
III
DAPA-CKD
|
c.4,000
patients with CKD, with and without T2D
|
Arm
1: Farxiga 10mg
or 5mg QD
Arm 2:
placebo
|
Time to
first occurrence of ≥ 50% sustained decline in
eGFR[57] or reaching
ESRD[58] or CV death
or renal death
|
FPCD
Q1
2017
LPCD
Q1
2020
|
Trial
stopped early based on recommendation from an IDMC
Fast
Track designation (US)
|
Brilinta
|
|
||||
Phase
III THEMIS
|
c.19,000
patients with T2D and CAD without a history of MI or
stroke
|
Arm
1: Brilinta 60mg
BID[59]
Arm 2:
placebo BID on a background of aspirin if not
contra-indicated[60] or not
tolerated
|
Composite
of CV death, non-fatal MI and non-fatal stroke
|
FPCD
Q1
2014
LPCD
Q2
2016
|
Primary
endpoint met
|
Phase
III
THALES
|
c.11,000
patients with acute ischaemic stroke or transient ischaemic
attack
|
Arm
1: Brilinta 90mg
BID
Arm 2:
placebo BID on a background of aspirin if not contra-indicated or
not tolerated
|
Prevention
of the composite of subsequent stroke and death at 30
days
|
FPCD
Q1
2018
LPCD
Q4
2019
|
Primary
endpoint met
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
Phase
III OSTRO
|
Patients
(aged 18-75 years) with severe bilateral nasal polyposis;
symptomatic, despite SoC
|
Placebo
or Fasenra 30mg
Q8W SC
|
Nasal-polyposis
burden and reported nasal blockage
|
FPCD
Q1
2018
LPCD
Q2
2019
Data
anticipated
H2
2020
|
Recruitment
completed
|
Phase
III RESOLUTE
|
Patients
with moderate to very severe COPD with a history of frequent COPD
exacerbations and elevated peripheral blood
eosinophils
|
Placebo
or Fasenra 100mg
Q8W SC
|
Annualised
rate of moderate or severe COPD exacerbations
|
FPCD
Q4
2019
Data
anticipated 2021+
|
Recruitment
ongoing
|
Phase
III
MANDARA
|
Eosinophilic
granulomatosis with polyangiitis
|
Fasenra 30mg or
mepolizumab
3x100mg Q4W
|
Proportion
of patients who achieve remission, defined as a score[61] =0 and an
OCS dose ≤4 mg/day at weeks 36 and 48
|
FPCD
Q4
2019
Data
anticipated
2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
Phase
III
NATRON
|
HES[62]
|
Placebo
or Fasenra 30mg
Q4W SC
|
Time to
HES worsening flare or any cytotoxic and/or immuno-suppressive
therapy increase or hospitalisation
|
FPCD
Q4
2019
Data
anticipated 2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
Phase
III
MESSINA
|
Eosinophilic
oesophagitis
|
Placebo
or Fasenra 30mg
Q4W SC
|
Proportion
of patients with a histologic response
Changes
from baseline in dysphagia PRO[63]
|
Data
anticipated 2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
Phase
III
FJORD
|
BP
|
Placebo
or Fasenra 30mg
Q4W SC
|
Proportion
of patients with partial or
complete
remission of BP whilst off OCS for ≥2 months
at Week
36
|
Data
anticipated 2021+
|
Initiating
|
For the quarter ended 31 March
|
2020
|
2019
|
$m
|
$m
|
|
Total Revenue
|
6,354
|
5,491
|
Product Sales
|
6,311
|
5,465
|
Collaboration Revenue
|
43
|
26
|
Cost of Sales
|
(1,420)
|
(1,129)
|
Gross Profit
|
4,934
|
4,362
|
Distribution costs
|
(87)
|
(78)
|
Research and development expense
|
(1,388)
|
(1,266)
|
Selling, general and administrative costs
|
(2,719)
|
(2,514)
|
Other operating income and expense
|
480
|
593
|
Operating Profit
|
1,220
|
1,097
|
Finance income
|
51
|
55
|
Finance expense
|
(332)
|
(367)
|
Share of after-tax losses in associates and joint
ventures
|
(4)
|
(27)
|
Profit Before Tax
|
935
|
758
|
Taxation
|
(185)
|
(195)
|
Profit for the period
|
750
|
563
|
Other comprehensive income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
440
|
10
|
Net gains on equity investments measured at fair value through
other comprehensive income
|
171
|
120
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
21
|
(1)
|
Tax on items that will not be reclassified to profit or
loss
|
(66)
|
(43)
|
|
566
|
86
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
(608)
|
53
|
Foreign exchange arising on designating borrowings in net
investment hedges
|
(380)
|
(180)
|
Fair value movements on cash flow hedges
|
(187)
|
(54)
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
45
|
47
|
Fair value movements on derivatives designated in net investment
hedges
|
60
|
3
|
Costs of hedging
|
(5)
|
(6)
|
Tax on items that may be reclassified subsequently to profit or
loss
|
73
|
23
|
|
(1,002)
|
(114)
|
Other comprehensive loss for the period, net of tax
|
(436)
|
(28)
|
Total comprehensive income for the period
|
314
|
535
|
Profit attributable to:
|
|
|
Owners of the Parent
|
780
|
593
|
Non-controlling interests
|
(30)
|
(30)
|
|
750
|
563
|
Total comprehensive income attributable to:
|
|
|
Owners of the Parent
|
345
|
565
|
Non-controlling interests
|
(31)
|
(30)
|
|
314
|
535
|
Basic earnings per $0.25 Ordinary Share
|
$0.59
|
$0.47
|
Diluted earnings per $0.25 Ordinary Share
|
$0.59
|
$0.47
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,312
|
1,267
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,313
|
1,268
|
|
At 31 Mar 2020
|
At 31 Dec 2019
|
At 31 Mar 2019
|
$m
|
$m
|
$m
|
|
Assets
|
|
|
|
Non-current assets
|
|
|
|
Property, plant and equipment
|
7,347
|
7,688
|
7,446
|
Right-of-use assets
|
644
|
647
|
707
|
Goodwill
|
11,569
|
11,668
|
11,674
|
Intangible assets
|
19,718
|
20,833
|
22,852
|
Investments in associates and joint ventures
|
44
|
58
|
76
|
Other investments
|
1,476
|
1,401
|
1,530
|
Derivative financial instruments
|
104
|
61
|
94
|
Other receivables
|
527
|
740
|
496
|
Deferred tax assets
|
2,960
|
2,718
|
2,531
|
|
44,389
|
45,814
|
47,406
|
Current assets
|
|
|
|
Inventories
|
3,123
|
3,193
|
3,050
|
Trade and other receivables
|
5,080
|
5,761
|
5,289
|
Other investments
|
752
|
849
|
822
|
Derivative financial instruments
|
61
|
36
|
234
|
Income tax receivable
|
262
|
285
|
118
|
Cash and cash equivalents
|
3,413
|
5,369
|
4,136
|
Assets held for sale
|
131
|
70
|
-
|
|
12,822
|
15,563
|
13,649
|
Total assets
|
57,211
|
61,377
|
61,055
|
Liabilities
|
|
|
|
Current liabilities
|
|
|
|
Interest-bearing loans and borrowings
|
(2,289)
|
(1,822)
|
(3,544)
|
Lease liabilities
|
(181)
|
(188)
|
(175)
|
Trade and other payables
|
(12,633)
|
(13,987)
|
(13,102)
|
Derivative financial instruments
|
(31)
|
(36)
|
(28)
|
Provisions
|
(649)
|
(723)
|
(397)
|
Income tax payable
|
(1,260)
|
(1,361)
|
(1,010)
|
|
(17,043)
|
(18,117)
|
(18,256)
|
Non-current liabilities
|
|
|
|
Interest-bearing loans and borrowings
|
(15,634)
|
(15,730)
|
(17,320)
|
Lease liabilities
|
(472)
|
(487)
|
(539)
|
Derivative financial instruments
|
(188)
|
(18)
|
(5)
|
Deferred tax liabilities
|
(2,501)
|
(2,490)
|
(3,267)
|
Retirement benefit obligations
|
(2,129)
|
(2,807)
|
(2,385)
|
Provisions
|
(807)
|
(841)
|
(379)
|
Other payables
|
(6,221)
|
(6,291)
|
(6,875)
|
|
(27,952)
|
(28,664)
|
(30,770)
|
Total liabilities
|
(44,995)
|
(46,781)
|
(49,026)
|
Net assets
|
12,216
|
14,596
|
12,029
|
Equity
|
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
|
Share capital
|
328
|
328
|
317
|
Share premium account
|
7,946
|
7,941
|
4,438
|
Other reserves
|
2,056
|
2,046
|
2,046
|
Retained earnings
|
448
|
2,812
|
3,682
|
|
10,778
|
13,127
|
10,483
|
Non-controlling interests
|
1,438
|
1,469
|
1,546
|
Total equity
|
12,216
|
14,596
|
12,029
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
At 1 Jan 2019
|
317
|
4,427
|
2,041
|
5,683
|
12,468
|
1,576
|
14,044
|
|
|
|
|
|
|
|
|
Adoption of new accounting standards
|
-
|
-
|
-
|
54
|
54
|
-
|
54
|
Profit for the period
|
-
|
-
|
-
|
593
|
593
|
(30)
|
563
|
Other comprehensive loss
|
-
|
-
|
-
|
(28)
|
(28)
|
-
|
(28)
|
Transfer to other reserves
|
-
|
-
|
5
|
(5)
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(2,403)
|
(2,403)
|
-
|
(2,403)
|
Issue of Ordinary Shares
|
-
|
11
|
-
|
-
|
11
|
-
|
11
|
Share-based payments charge for the period
|
-
|
-
|
-
|
53
|
53
|
-
|
53
|
Settlement of share plan awards
|
-
|
-
|
-
|
(265)
|
(265)
|
-
|
(265)
|
|
|
|
|
|
|
|
|
Net movement
|
-
|
11
|
5
|
(2,001)
|
(1,985)
|
(30)
|
(2,015)
|
|
|
|
|
|
|
|
|
At 31 Mar 2019
|
317
|
4,438
|
2,046
|
3,682
|
10,483
|
1,546
|
12,029
|
|
|
|
|
|
|
|
|
At 1 Jan 2020
|
328
|
7,941
|
2,046
|
2,812
|
13,127
|
1,469
|
14,596
|
|
|
|
|
|
|
|
|
Profit for the period
|
-
|
-
|
-
|
780
|
780
|
(30)
|
750
|
Other comprehensive loss
|
-
|
-
|
-
|
(435)
|
(435)
|
(1)
|
(436)
|
Transfer to other reserves
|
-
|
-
|
10
|
(10)
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
-
|
Dividends
|
-
|
-
|
-
|
(2,489)
|
(2,489)
|
-
|
(2,489)
|
Issue of Ordinary Shares
|
-
|
5
|
-
|
-
|
5
|
-
|
5
|
Share-based payments charge for the period
|
-
|
-
|
-
|
53
|
53
|
-
|
53
|
Settlement of share plan awards
|
-
|
-
|
-
|
(263)
|
(263)
|
-
|
(263)
|
Net movement
|
-
|
5
|
10
|
(2,364)
|
(2,349)
|
(31)
|
(2,380)
|
|
|
|
|
|
|
|
|
At 31 Mar 2020
|
328
|
7,946
|
2,056
|
448
|
10,778
|
1,438
|
12,216
|
For the quarter ended 31 March
|
2020
|
2019
|
$m
|
$m
|
|
Cash flows from operating activities
|
|
|
Profit Before Tax
|
935
|
758
|
Finance income and expense
|
281
|
312
|
Share of after-tax losses of associates and joint
ventures
|
4
|
27
|
Depreciation, amortisation and impairment
|
841
|
676
|
Increase in working capital and short-term provisions
|
(445)
|
(710)
|
Gains on disposal of intangible assets
|
(358)
|
(512)
|
Fair value movements on contingent consideration arising from
business combinations
|
(33)
|
8
|
Non-cash and other movements
|
(429)
|
(404)
|
Cash generated from operations
|
796
|
155
|
Interest paid
|
(180)
|
(208)
|
Tax paid
|
(477)
|
(334)
|
Net cash inflow/(outflow) from operating activities
|
139
|
(387)
|
Cash flows from investing activities
|
|
|
Payment of contingent consideration from business
combinations
|
(167)
|
(219)
|
Purchase of property, plant and equipment
|
(186)
|
(174)
|
Disposal of property, plant and equipment
|
-
|
28
|
Purchase of intangible assets
|
(190)
|
(586)
|
Disposal of intangible assets
|
365
|
1,071
|
Movement
in profit-participation liability
|
-
|
150
|
Purchase of non-current asset investments
|
(115)
|
(3)
|
Disposal of non-current asset investments
|
184
|
17
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
98
|
20
|
Payments to associates and joint ventures
|
(8)
|
(12)
|
Interest received
|
28
|
36
|
Net cash inflow from investing activities
|
9
|
328
|
Net cash inflow/(outflow) before financing activities
|
148
|
(59)
|
Cash flows from financing activities
|
|
|
Proceeds from issue of share capital
|
6
|
11
|
Issue of loans
|
-
|
500
|
Dividends paid
|
(2,398)
|
(2,432)
|
Hedge contracts relating to dividend payments
|
(93)
|
26
|
Repayment of obligations under leases
|
(53)
|
(42)
|
Movement in short-term borrowings
|
176
|
1,239
|
Net cash outflow from financing activities
|
(2,362)
|
(698)
|
Net decrease in cash and cash equivalents in the
period
|
(2,214)
|
(757)
|
Cash and cash equivalents at the beginning of the
period
|
5,223
|
4,671
|
Exchange rate effects
|
(32)
|
12
|
Cash and cash equivalents at the end of the period
|
2,977
|
3,926
|
Cash and cash equivalents consist of:
|
|
|
Cash and cash equivalents
|
3,413
|
4,136
|
Overdrafts
|
(436)
|
(210)
|
|
2,977
|
3,926
|
|
At 1 Jan 2020
|
Cash flow
|
Non-cash & other
|
Exchange movements
|
At 31 Mar 2020
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Non-current instalments of loans
|
(15,730)
|
-
|
7
|
89
|
(15,634)
|
Non-current instalments of leases
|
(487)
|
-
|
-
|
15
|
(472)
|
|
|
|
|
|
|
Total long-term debt
|
(16,217)
|
-
|
7
|
104
|
(16,106)
|
|
|
|
|
|
|
Current instalments of loans
|
(1,597)
|
-
|
(1)
|
-
|
(1,598)
|
Current instalments of leases
|
(188)
|
58
|
(56)
|
5
|
(181)
|
Commercial paper
|
-
|
(85)
|
-
|
-
|
(85)
|
Bank collateral
|
(71)
|
(93)
|
-
|
-
|
(164)
|
Other short-term borrowings excluding overdrafts
|
(8)
|
2
|
-
|
-
|
(6)
|
Overdraft
|
(146)
|
(297)
|
-
|
7
|
(436)
|
|
|
|
|
|
|
Total current debt
|
(2,010)
|
(415)
|
(57)
|
12
|
(2,470)
|
|
|
|
|
|
|
Gross borrowings
|
(18,227)
|
(415)
|
(50)
|
116
|
(18,576)
|
|
|
|
|
|
|
Net derivative financial instruments
|
43
|
93
|
(190)
|
-
|
(54)
|
|
|
|
|
|
|
Net borrowings
|
(18,184)
|
(322)
|
(240)
|
116
|
(18,630)
|
|
|
|
|
|
|
Cash and cash equivalents
|
5,369
|
(1,917)
|
-
|
(39)
|
3,413
|
Other investments - current
|
849
|
(98)
|
6
|
(5)
|
752
|
Other investments - non-current
|
62
|
-
|
(10)
|
-
|
52
|
Cash and investments
|
6,280
|
(2,015)
|
(4)
|
(44)
|
4,217
|
|
|
|
|
|
|
Net Debt
|
(11,904)
|
(2,337)
|
(244)
|
72
|
(14,413)
|
|
2020
|
2019
|
||
Diabetes alliance
|
Other
|
Total
|
Total
|
|
$m
|
$m
|
$m
|
$m
|
|
At 1 January
|
3,300
|
839
|
4,139
|
5,106
|
Settlements
|
(124)
|
(43)
|
(167)
|
(219)
|
Revaluations
|
(22)
|
(11)
|
(33)
|
8
|
Discount unwind
|
57
|
16
|
73
|
90
|
|
|
|
|
|
At 31 March
|
3,211
|
801
|
4,012
|
4,985
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
Actual
|
Actual
|
CER
|
Actual
|
CER
|
||||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
982
|
56
|
58
|
280
|
n/m
|
n/m
|
371
|
43
|
162
|
62
|
66
|
169
|
27
|
26
|
Imfinzi
|
462
|
57
|
57
|
33
|
n/m
|
n/m
|
286
|
24
|
75
|
n/m
|
n/m
|
68
|
94
|
93
|
Lynparza
|
397
|
67
|
69
|
56
|
n/m
|
n/m
|
197
|
66
|
102
|
57
|
61
|
42
|
57
|
56
|
Calquence
|
88
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
86
|
n/m
|
-
|
-
|
-
|
1
|
n/m
|
n/m
|
Zoladex*
|
225
|
16
|
19
|
149
|
30
|
35
|
2
|
24
|
35
|
1
|
3
|
39
|
(10)
|
(9)
|
Faslodex*
|
166
|
(35)
|
(34)
|
48
|
7
|
10
|
23
|
(83)
|
64
|
19
|
22
|
31
|
7
|
5
|
Iressa*
|
77
|
(42)
|
(41)
|
62
|
(28)
|
(26)
|
4
|
(2)
|
5
|
(79)
|
(78)
|
6
|
(69)
|
(69)
|
Arimidex*
|
50
|
(1)
|
1
|
41
|
16
|
20
|
-
|
-
|
1
|
(85)
|
(85)
|
8
|
(14)
|
(15)
|
Casodex*
|
42
|
(12)
|
(10)
|
33
|
8
|
11
|
-
|
-
|
1
|
(84)
|
(84)
|
8
|
(37)
|
(37)
|
Others
|
13
|
(37)
|
(36)
|
8
|
(11)
|
(9)
|
1
|
-
|
1
|
19
|
23
|
3
|
(60)
|
(61)
|
Total Oncology
|
2,502
|
32
|
34
|
711
|
45
|
49
|
970
|
26
|
446
|
42
|
46
|
375
|
18
|
17
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
405
|
16
|
19
|
141
|
49
|
55
|
113
|
(14)
|
116
|
30
|
34
|
35
|
2
|
3
|
Brilinta
|
408
|
17
|
19
|
134
|
38
|
42
|
165
|
8
|
93
|
12
|
15
|
16
|
8
|
10
|
Bydureon
|
100
|
(30)
|
(29)
|
1
|
(41)
|
(39)
|
84
|
(28)
|
12
|
(34)
|
(32)
|
3
|
(46)
|
(44)
|
Onglyza
|
141
|
(8)
|
(6)
|
47
|
10
|
13
|
67
|
(14)
|
15
|
(19)
|
(17)
|
12
|
(10)
|
(10)
|
Byetta
|
20
|
(32)
|
(31)
|
3
|
n/m
|
n/m
|
11
|
(42)
|
4
|
(37)
|
(35)
|
2
|
(17)
|
(13)
|
Other diabetes
|
13
|
16
|
18
|
2
|
n/m
|
n/m
|
7
|
(9)
|
3
|
50
|
56
|
1
|
-
|
-
|
Lokelma
|
11
|
n/m
|
n/m
|
-
|
-
|
-
|
10
|
n/m
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
Roxadustat
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Crestor*
|
301
|
(10)
|
(9)
|
192
|
(15)
|
(13)
|
28
|
9
|
34
|
(12)
|
(10)
|
47
|
4
|
4
|
Seloken/Toprol-XL*
|
177
|
(21)
|
(18)
|
166
|
(14)
|
(11)
|
4
|
(82)
|
4
|
(29)
|
(29)
|
3
|
(2)
|
2
|
Atacand*
|
66
|
33
|
36
|
49
|
25
|
29
|
3
|
33
|
8
|
n/m
|
n/m
|
6
|
32
|
36
|
Others
|
59
|
(18)
|
(17)
|
37
|
(28)
|
(27)
|
-
|
-
|
19
|
7
|
9
|
3
|
22
|
22
|
BioPharmaceuticals: total CVRM
|
1,701
|
(1)
|
1
|
772
|
3
|
6
|
492
|
(12)
|
309
|
9
|
12
|
128
|
2
|
3
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
790
|
35
|
36
|
156
|
17
|
20
|
310
|
76
|
195
|
7
|
10
|
129
|
37
|
37
|
Pulmicort
|
380
|
(1)
|
-
|
313
|
-
|
1
|
23
|
(3)
|
26
|
3
|
6
|
18
|
(8)
|
(8)
|
Fasenra
|
199
|
54
|
55
|
6
|
-
|
-
|
120
|
29
|
46
|
n/m
|
n/m
|
27
|
53
|
53
|
Daliresp/Daxas
|
53
|
11
|
12
|
1
|
(8)
|
(4)
|
45
|
10
|
7
|
17
|
21
|
-
|
-
|
-
|
Bevespi
|
12
|
22
|
22
|
-
|
-
|
-
|
12
|
15
|
-
|
-
|
-
|
-
|
-
|
-
|
Breztri
|
4
|
n/m
|
n/m
|
4
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Others
|
113
|
(11)
|
(10)
|
59
|
(14)
|
(12)
|
2
|
38
|
46
|
(15)
|
(13)
|
6
|
n/m
|
n/m
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,551
|
21
|
22
|
539
|
4
|
6
|
512
|
48
|
320
|
12
|
15
|
180
|
34
|
34
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
338
|
(7)
|
(6)
|
187
|
(2)
|
1
|
40
|
(39)
|
22
|
36
|
41
|
89
|
(3)
|
(3)
|
Synagis
|
85
|
61
|
61
|
5
|
n/m
|
n/m
|
7
|
(72)
|
73
|
n/m
|
n/m
|
-
|
-
|
-
|
Losec/Prilosec
|
54
|
(30)
|
(28)
|
44
|
(14)
|
(12)
|
2
|
96
|
5
|
(74)
|
(74)
|
3
|
(47)
|
(48)
|
Seroquel XR/IR
|
36
|
(4)
|
(3)
|
12
|
(17)
|
(15)
|
13
|
n/m
|
8
|
(67)
|
(67)
|
3
|
(47)
|
(48)
|
Others
|
44
|
(8)
|
(7)
|
1
|
n/m
|
n/m
|
25
|
(9)
|
15
|
6
|
9
|
3
|
(82)
|
(82)
|
Total other medicines
|
557
|
(4)
|
(3)
|
249
|
-
|
2
|
87
|
(23)
|
123
|
23
|
25
|
98
|
(15)
|
(16)
|
Total Product Sales
|
6,311
|
15
|
17
|
2,271
|
13
|
16
|
2,061
|
15
|
1,198
|
22
|
25
|
781
|
13
|
12
|
|
Q1 2020
|
||
$m
|
% change
|
||
Actual
|
CER
|
||
Oncology
|
|
|
|
Tagrisso
|
982
|
11
|
11
|
Imfinzi
|
462
|
9
|
9
|
Lynparza
|
397
|
13
|
13
|
Calquence
|
88
|
58
|
58
|
Zoladex*
|
225
|
15
|
15
|
Faslodex*
|
166
|
-
|
-
|
Iressa*
|
77
|
(3)
|
(4)
|
Arimidex*
|
50
|
(1)
|
(2)
|
Casodex*
|
42
|
(2)
|
(3)
|
Others
|
13
|
(52)
|
(52)
|
Total Oncology
|
2,502
|
10
|
10
|
BioPharmaceuticals: CVRM
|
|
|
|
Farxiga
|
405
|
(3)
|
(3)
|
Brilinta
|
408
|
(5)
|
(5)
|
Bydureon
|
100
|
(28)
|
(28)
|
Onglyza
|
141
|
8
|
8
|
Byetta
|
20
|
(24)
|
(24)
|
Other diabetes
|
13
|
(22)
|
(22)
|
Lokelma
|
11
|
42
|
42
|
Roxadustat
|
-
|
-
|
-
|
Crestor*
|
301
|
2
|
1
|
Seloken/Toprol-XL*
|
177
|
(6)
|
(6)
|
Atacand*
|
66
|
11
|
12
|
Others
|
59
|
(21)
|
(22)
|
BioPharmaceuticals: total CVRM
|
1,701
|
(5)
|
(5)
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
Symbicort
|
790
|
11
|
11
|
Pulmicort
|
380
|
(8)
|
(9)
|
Fasenra
|
199
|
(3)
|
(3)
|
Daliresp/Daxas
|
53
|
(8)
|
(8)
|
Bevespi
|
12
|
9
|
9
|
Breztri
|
4
|
n/m
|
n/m
|
Others
|
113
|
(16)
|
(17)
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,551
|
1
|
1
|
Other medicines
|
|
|
|
Nexium
|
338
|
(4)
|
(4)
|
Synagis
|
85
|
35
|
35
|
Losec/Prilosec
|
54
|
18
|
17
|
Seroquel XR/IR
|
36
|
(12)
|
(12)
|
Others
|
44
|
(71)
|
(70)
|
Total other medicines
|
557
|
(15)
|
(15)
|
Total Product Sales
|
6,311
|
1
|
1
|
|
Q1 2019
|
Q2 2019
|
Q3 2019
|
Q4 2019
|
||||||||
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
Actual
|
CER
|
Actual
|
CER
|
|||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
630
|
6
|
6
|
784
|
24
|
25
|
891
|
14
|
13
|
884
|
(1)
|
-
|
Imfinzi
|
295
|
13
|
13
|
338
|
15
|
15
|
412
|
22
|
22
|
424
|
3
|
4
|
Lynparza
|
237
|
13
|
13
|
283
|
19
|
20
|
327
|
16
|
15
|
351
|
7
|
8
|
Calquence
|
29
|
21
|
23
|
35
|
21
|
19
|
44
|
27
|
27
|
56
|
25
|
25
|
Faslodex*
|
254
|
(6)
|
(6)
|
267
|
5
|
6
|
205
|
(23)
|
(23)
|
166
|
(20)
|
(19)
|
Zoladex*
|
194
|
7
|
6
|
197
|
2
|
1
|
226
|
15
|
16
|
196
|
(14)
|
(12)
|
Iressa*
|
134
|
20
|
18
|
118
|
(12)
|
(11)
|
91
|
(23)
|
(22)
|
80
|
(13)
|
(12)
|
Arimidex*
|
51
|
11
|
10
|
60
|
18
|
17
|
63
|
5
|
5
|
51
|
(20)
|
(18)
|
Casodex*
|
48
|
4
|
3
|
57
|
19
|
18
|
52
|
(8)
|
(6)
|
43
|
(18)
|
(17)
|
Others
|
20
|
(13)
|
(14)
|
28
|
40
|
29
|
20
|
(27)
|
(22)
|
26
|
30
|
26
|
Total Oncology
|
1,892
|
7
|
6
|
2,167
|
15
|
15
|
2,334
|
8
|
8
|
2,274
|
(3)
|
(2)
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
349
|
(12)
|
(12)
|
377
|
8
|
9
|
398
|
5
|
5
|
419
|
5
|
6
|
Brilinta
|
348
|
(7)
|
(8)
|
389
|
12
|
12
|
416
|
7
|
8
|
428
|
3
|
3
|
Bydureon
|
142
|
3
|
3
|
141
|
(1)
|
-
|
127
|
(10)
|
(10)
|
139
|
9
|
10
|
Onglyza
|
153
|
3
|
3
|
116
|
(24)
|
(24)
|
127
|
9
|
11
|
131
|
3
|
4
|
Byetta
|
30
|
(6)
|
(5)
|
25
|
(17)
|
(16)
|
28
|
10
|
13
|
27
|
(2)
|
(4)
|
Other diabetes
|
11
|
(8)
|
(17)
|
11
|
-
|
8
|
14
|
26
|
22
|
16
|
17
|
17
|
Lokelma
|
-
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
4
|
n/m
|
n/m
|
8
|
87
|
74
|
Roxadustat
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Crestor*
|
335
|
(5)
|
(6)
|
310
|
(7)
|
(7)
|
337
|
9
|
9
|
296
|
(12)
|
(11)
|
Seloken/Toprol-XL*
|
225
|
41
|
38
|
168
|
(25)
|
(25)
|
177
|
6
|
8
|
190
|
7
|
8
|
Atacand*
|
50
|
(14)
|
(15)
|
56
|
12
|
14
|
55
|
(1)
|
(1)
|
60
|
8
|
9
|
Others
|
71
|
(3)
|
(5)
|
63
|
(11)
|
(8)
|
65
|
4
|
2
|
72
|
13
|
16
|
BioPharmaceuticals: total CVRM
|
1,714
|
(2)
|
(3)
|
1,658
|
(3)
|
(3)
|
1,749
|
5
|
6
|
1,785
|
2
|
3
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
585
|
(8)
|
(8)
|
585
|
-
|
1
|
613
|
5
|
4
|
712
|
16
|
17
|
Pulmicort
|
383
|
(2)
|
(2)
|
333
|
(13)
|
(13)
|
337
|
1
|
3
|
413
|
22
|
23
|
Fasenra
|
129
|
3
|
4
|
167
|
29
|
30
|
202
|
21
|
21
|
206
|
2
|
2
|
Daliresp/Daxas
|
48
|
(11)
|
(12)
|
56
|
17
|
18
|
53
|
(6)
|
(7)
|
58
|
10
|
10
|
Bevespi
|
10
|
-
|
(5)
|
10
|
-
|
2
|
10
|
4
|
8
|
12
|
8
|
5
|
Breztri
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
-
|
-
|
1
|
(74)
|
(73)
|
Others
|
128
|
(14)
|
(12)
|
101
|
(21)
|
(23)
|
102
|
1
|
(1)
|
135
|
33
|
38
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,283
|
(6)
|
(6)
|
1,252
|
(2)
|
(2)
|
1,319
|
5
|
6
|
1,537
|
17
|
17
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
363
|
(7)
|
(8)
|
393
|
8
|
8
|
374
|
(5)
|
(4)
|
353
|
(6)
|
(6)
|
Synagis
|
53
|
(79)
|
(79)
|
96
|
81
|
81
|
146
|
52
|
53
|
63
|
(57)
|
(57)
|
Losec/Prilosec
|
76
|
27
|
26
|
68
|
(11)
|
(10)
|
73
|
8
|
9
|
46
|
(38)
|
(38)
|
Seroquel XR/IR
|
37
|
(34)
|
(33)
|
32
|
(14)
|
(10)
|
82
|
n/m
|
n/m
|
40
|
(50)
|
(49)
|
Others
|
47
|
(65)
|
(64)
|
52
|
11
|
11
|
56
|
8
|
-
|
151
|
n/m
|
n/m
|
Total other medicines
|
576
|
(35)
|
(36)
|
641
|
11
|
12
|
731
|
14
|
14
|
653
|
(11)
|
(10)
|
Total Product Sales
|
5,465
|
(5)
|
(6)
|
5,718
|
5
|
5
|
6,132
|
7
|
8
|
6,250
|
2
|
3
|
|
|
Q1 2020
|
Q1 2019
|
FY 2019
|
FY 2018
|
$m
|
$m
|
$m
|
$m
|
||
Initial Collaboration Revenue
|
Crestor (Spain)
|
-
|
-
|
-
|
61
|
Ongoing Collaboration Revenue
|
Lynparza: regulatory
milestones
|
-
|
-
|
60
|
140
|
Lynparza: sales
milestones
|
-
|
-
|
450
|
250
|
|
Lynparza/selumetinib: option
payments
|
-
|
-
|
100
|
400
|
|
Crestor (Spain)
|
-
|
-
|
39
|
|
|
Enhertu: profit
share
|
14
|
-
|
-
|
-
|
|
Roxadustat: profit share
|
3
|
-
|
-
|
-
|
|
Royalty income
|
17
|
16
|
62
|
49
|
|
|
Other Collaboration Revenue
|
9
|
10
|
108
|
141
|
|
Total
|
43
|
26
|
819
|
1,041
|
Divestment/other
|
Q1 2020
|
Q1 2019
|
FY 2019
|
FY 2018
|
$m
|
$m
|
$m
|
$m
|
|
Hypertension medicines (ex-US, India and Japan)
|
350
|
-
|
-
|
-
|
Synagis (US)
|
-
|
515
|
515
|
-
|
Losec (ex-China, Japan, US
and Mexico)
|
-
|
-
|
243
|
-
|
Seroquel and Seroquel XR (US, Canada, Europe and
Russia)
|
-
|
-
|
213
|
-
|
Arimidex and Casodex (various countries)
|
-
|
-
|
181
|
-
|
Nexium (Europe)
and Vimovo (ex-US)
|
-
|
-
|
-
|
728
|
Seroquel
|
-
|
-
|
-
|
527
|
Legal settlement[67]
|
-
|
-
|
-
|
346
|
Atacand
|
-
|
-
|
-
|
210
|
Anaesthetics
|
-
|
-
|
-
|
172
|
Alvesco, Omnaris and Zetonna
|
-
|
-
|
-
|
139
|
Other
|
130
|
78
|
389
|
405
|
Total
|
480
|
593
|
1,541
|
2,527
|
Announcement of
first half and second quarter
results
30 July
2020
|
|
|
Announcement of
year to date and third quarter
results
5 November
2020
|
|
|
|
||
Future
dividends will normally be paid as follows:
|
||
First
interim:
|
announced
with half-year and second-quarter results and paid in
September
|
|
Second
interim:
|
announced
with full-year and fourth-quarter results and paid in
March
|
|
|
|
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
+44 (0) 121 415 7033
|
|
+1 (718) 921 8137
|
|
|
|
db@astfinancial.com
|
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|